Grace Therapeutics, Inc. (GRCE)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Grace Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | 1.80 | 2.01 | 1.70 | 1.84 | 231,476 |
| Nov 2, 2026 | 1.93 | 1.95 | 1.76 | 1.81 | 99,539 |
| Oct 30, 2026 | 1.95 | 1.98 | 1.87 | 1.94 | 85,940 |
| Oct 29, 2026 | 1.99 | 2.05 | 1.88 | 1.94 | 75,993 |
| Oct 28, 2026 | 1.87 | 2.03 | 1.87 | 2.01 | 164,695 |
| Oct 27, 2026 | 1.80 | 1.90 | 1.80 | 1.87 | 110,536 |
| Oct 26, 2026 | 1.94 | 1.99 | 1.67 | 1.81 | 487,802 |
| Oct 23, 2026 | 1.91 | 1.95 | 1.88 | 1.93 | 47,222 |
| Oct 22, 2026 | 1.91 | 1.93 | 1.87 | 1.92 | 97,097 |
| Oct 21, 2026 | 1.96 | 2.02 | 1.94 | 1.97 | 77,141 |
| Oct 20, 2026 | 1.90 | 2.07 | 1.89 | 1.98 | 94,407 |
| Oct 19, 2026 | 1.89 | 1.97 | 1.82 | 1.88 | 90,432 |
| Oct 16, 2026 | 1.97 | 2.03 | 1.85 | 1.89 | 168,796 |
| Oct 15, 2026 | 1.91 | 1.97 | 1.89 | 1.95 | 109,289 |
| Oct 14, 2026 | 1.97 | 2.01 | 1.85 | 1.89 | 177,973 |
| Oct 13, 2026 | 2.00 | 2.02 | 1.97 | 1.99 | 52,407 |
| Oct 12, 2026 | 2.02 | 2.06 | 1.98 | 2.02 | 50,631 |
| Oct 9, 2026 | 2.05 | 2.09 | 2.03 | 2.08 | 37,794 |
| Oct 8, 2026 | 2.05 | 2.07 | 2.00 | 2.04 | 52,592 |
| Oct 7, 2026 | 2.06 | 2.12 | 2.05 | 2.10 | 84,253 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Opaleye Management Inc. | 10% Owner | Purchase | 66.4K | $117.4K | Oct 26, 2026 |
| Opaleye Management Inc. | 10% Owner | Purchase | 21.4K | $41.2K | Oct 22, 2026 |
| Opaleye Management Inc. | 10% Owner | Purchase | 4.3K | $8.0K | Oct 19, 2026 |
| Opaleye Management Inc. | 10% Owner | Purchase | 36.3K | $68.8K | Oct 16, 2026 |
| Opaleye Management Inc. | 10% Owner | Purchase | 23.5K | $45.7K | Oct 15, 2026 |
| Opaleye Management Inc. | 10% Owner | Purchase | 11.2K | $21.7K | Oct 14, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
ADAR1 Capital Management GP, LLC · filed May 2026 | 1.7M | 8.2% | 13G |
Nantahala Capital Management, LLC · filed Feb 2026 | 1.6M | 7.5% | 13G |
Cerity Partners LLC | 849.1K | 4.0% | 13F |
AIGH Capital Management LLC · joint filing· may incl. warrants· filed Apr 2026 | 814.0K | 3.9% | 13G |
Eversept Partners, LP | 772.9K | 3.7% | 13F |
BANK OF AMERICA CORP /DE/ | 494.7K | 2.4% | 13F |
BANK OF AMERICA CORP /DE/ 56-0906609 · also on 13F· may incl. warrants· filed Nov 2024 | 494.7K | 2.4% | 13G |
VANGUARD CAPITAL MANAGEMENT LLC | 411.7K | 2.0% | 13F |
CITADEL ADVISORS LLC | 349.7K | 1.7% | 13F |
Maven Securities LTD | 200.0K | 1.0% | 13F |
Insiders
- Opaleye Management Inc.10% Owner
- Kottayil GeorgeDirector
- NEUGEBOREN EDWARDDirector
- DAVIS A BRIANDirector
- Kavuru VimalDirector
- Kohli PrashantChief Executive Officer
- Kumar AmreshVP Program Management
- DelAversano Robert JPrincipal Financial Officer
- Macdonald R. LochChief Medical Officer
- D'Andrea CarrieVP Clinical Operations
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada.
The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage.
Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024.
The company's main offices are located in Princeton, New Jersey.
based on 21.04M shares outstanding
US30d Avg
117.56K
60d Avg
137.76K
90d Avg
132.75K